drugset
Drugs / Cipargamin
last change Jul 2026 re-read 9 days ago

Cipargamin

also known as KAE609 · Cipargamina · Cipargamine · NITD609

Small molecule

Developed for
Plasmodium falciparum malaria · malaria
Investigated by
Novartis Pharmaceuticals · Wellcome Trust · European and Developing Countries Clinical Trials Partnership (EDCTP) · Medicine for Malaria Venture

Trials 11

today NCT07811908 · Ph 2 NCT07811882 · Ph 2 NCT07235033 · Ph 2 NCT05750628 · Ph 2 NCT04675931 · Ph 2 NCT04321252 · Ph 1 NCT03334747 · Ph 2 NCT02543086 · Ph 1 NCT01836458 · Ph 2 NCT01860989 · Ph 2 NCT01524341 · Ph 2
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04321252 Jul → Nov 2020 malaria Novartis Pharmaceuticals Completed No outcome recorded
Phase 1 NCT02543086 Jul → Sep 2015 Plasmodium falciparum malaria Novartis Pharmaceuticals Terminated No outcome recorded
Phase 29 trials · 1 met primary
Phase 2 NCT07811908 Feb 2026 → Feb 2027 expected Plasmodium falciparum malaria Novartis Pharmaceuticals Recruiting No outcome recorded
Phase 2 NCT07811882 Oct 2025 → Jun 2026 Plasmodium falciparum malaria Novartis Pharmaceuticals Completed No outcome recorded
Phase 2 NCT07235033 Jan 2024 → Mar 2025 Plasmodium falciparum malaria Novartis Pharmaceuticals Completed Met primary
Phase 2 NCT05750628 Jan 2024 → Jun 2026 overdue Plasmodium falciparum malaria Novartis Pharmaceuticals Recruiting No outcome recorded
Phase 2 NCT04675931 Mar 2022 → Jul 2025 Plasmodium falciparum malaria Novartis Pharmaceuticals Completed No outcome recorded
Phase 2 NCT03334747 Nov 2017 → Nov 2019 malaria Novartis Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01836458 Jan 2014 → Mar 2015 malaria Novartis Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01860989 Jul 2013 → Aug 2014 — Novartis Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01524341 Jan → Jun 2012 malaria Novartis Pharmaceuticals Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as cipargamin “This first-in-human study assessed safety, tolerability, and pharmacokinetics (PK) of cipargamin (intravenous) in healthy adults.” PMID 39058022 ↗ Jul 2024
5

“the new antimalarial cipargamin (KAE609) in adults with uncomplicated Plasmodium falciparum malaria” PMID 27872070 ↗ Jan 2017

“KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases)” PMID 25075833 ↗ Jul 2014

“oral KAE609 (Cipargamin)” NCT05750628 ↗

NCT07811882 ↗

NCT04675931 ↗
Known as Cipargamina ChEMBL registry synonym — accepted as the source's own label CHEMBL1082723 ↗
Known as Cipargamine ChEMBL registry synonym — accepted as the source's own label CHEMBL1082723 ↗
Known as KAE609 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01836458 ↗
8

NCT07811908 ↗

NCT05750628 ↗

NCT02543086 ↗

NCT01524341 ↗

NCT03334747 ↗

NCT07235033 ↗

NCT04321252 ↗

NCT01860989 ↗
Known as NITD609 “KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases)” PMID 25075833 ↗ Jul 2014
Modality Small molecule “is a new synthetic antimalarial spiroindolone analogue” PMID 25075833 ↗ Jul 2014
Route Oral “KAE609 was supplied as capsules for oral use.” NCT01524341 ↗